GlassScriptPhysician profile
Louis Olegario
NPI 1245243955
$5,034.44
in general payments reported to CMS, 2019-2025
23 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $256 · 2021: $912 · 2022: $591 · 2023: $960 · 2024: $844 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,832.79 | 2019-2025 | Eterna, Proclaim |
| Boston Scientific Corporation | $1,168.09 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Nevro Corp. | $481.94 | 2022-2024 | Senza |
| Medtronic, INC. | $280.36 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Collegium Pharmaceutical, INC. | $263.40 | 2021-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.20 | 2022-2024 | Relistor |
| Medtronic USA, INC. | $142.97 | 2019 | |
| Averitas Pharma INC. | $129.01 | 2024-2025 | Qutenza |
| Grt US Holding, INC. | $83.98 | 2022 | |
| Valinor Pharma, LLC | $76.26 | 2023-2024 | Movantik |
| Protega Pharmaceutials INC | $61.60 | 2025 | Roxybond |
| Nalu Medical, INC. | $42.50 | 2025 | Nalu Neurostimulation System |
| Hikma Pharmaceuticals USA | $40.03 | 2022 | |
| Bioventus LLC | $37.57 | 2024 | Gelsyn-3 |
| Si-Bone, INC. | $22.77 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.24 | 2020 | |
| Vertos Medical, INC. | $21.93 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.39 | 2025 | |
| Pfizer INC. | $18.14 | 2021 | |
| Biodelivery Sciences International, INC. | $16.52 | 2021 | |
| Mdd US Operations, LLC | $14.05 | 2019 | |
| Saluda Medical Americas, INC. | $13.70 | 2024 | Evoke |
| Stimwave Technologies Incorporated | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Olegario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.